Baidu
map

AJC:脑钠肽(BNP)或可预测卒中患者新发房颤

2012-02-25 MedSci MedSci原创

 《美国心脏病学杂志》(Am J Cardiol)2012年2月17日在线发表日本的一项前瞻性研究表明,脑钠肽(BNP)水平或可预测急性缺血性卒中患者的新发房颤(AF),升高的BNP水平与新发房颤的高检出率相关。   该研究旨在评估BNP水平与缺血性卒中后新发AF检出率之间的关系。研究前瞻性连续纳入584例24小时内发病的缺血性卒中患者,其中入院时有心电图证实的房颤或房颤病史的患者被排除。采用

 《美国心脏病学杂志》(Am J Cardiol)2012年2月17日在线发表日本的一项前瞻性研究表明,脑钠肽(BNP)水平或可预测急性缺血性卒中患者的新发房颤(AF),升高的BNP水平与新发房颤的高检出率相关。

  该研究旨在评估BNP水平与缺血性卒中后新发AF检出率之间的关系。研究前瞻性连续纳入584例24小时内发病的缺血性卒中患者,其中入院时有心电图证实的房颤或房颤病史的患者被排除。采用多因素logistic回归分析,衡量入院时的血浆BNP水平等因素与新发房颤之间的相关性。此外,研究还评价了依据BNP水平的AF检出率。

  研究证实,有40例患者检测出AF(新发AF组;6.8%)。新发AF组的中位BNP水平显著高于非AF组(186.6 pg/ml,四分位数间距为68.7至386.3;比35.2 pg/ml,四分位数间距为15.9至80.1,P<0.0001)。新发AF组区别于非AF组BNP水平的截断值、灵敏度和特异度分别为65.0 pg/ml,80%和70%。

  多因素logistic回归分析表明,美国国立卫生研究院卒中量表评分(NIHSS)> 7(比值比3.4,95%可信区间1.685至70.06,P=0.0007)和血浆BNP水平> 65.0 pg/ml(比值比为6.8,95%可信区间2.975至15.359,P <0.0001)与新发AF独立相关。根据BNP水平的房颤检出率分别为:2%的患者<50 pg / ml,4%为50-100 pg / ml,12%为100-200 pg / ml,26%为200-400 pg / ml,38%为≥400 pg / ml。

  链接:

  Brain Natriuretic Peptide Levels as a Predictor for New Atrial Fibrillation During Hospitalization in Patients With Acute Ischemic Stroke

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2015-09-27 bewagi

    Hey, sutlbe must be your middle name. Great post!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2012-03-08 by2017
  3. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2012-06-19 vichy

    Too many complinmets too little space, thanks!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2012-02-26 huiwelcome
  6. [GetPortalCommentsPageByObjectIdResponse(id=37357, encodeId=5c4f3e35737, content=Hey, sutlbe must be your middle name. Great post!, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=bewagi, createdTime=Sun Sep 27 07:08:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654237, encodeId=e657165423ed1, content=<a href='/topic/show?id=9ee8851666c' target=_blank style='color:#2F92EE;'>#脑钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85166, encryptionId=9ee8851666c, topicName=脑钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad2e24479777, createdName=by2017, createdTime=Thu Mar 08 02:23:00 CST 2012, time=2012-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719986, encodeId=031f1e199860b, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jul 30 18:23:00 CST 2012, time=2012-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4390, encodeId=63a243908e, content=Too many complinmets too little space, thanks!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=vichy, createdTime=Tue Jun 19 23:12:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289277, encodeId=6dd612892e7ec, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481360, encodeId=da671481360fa, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sun Feb 26 15:23:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]

相关资讯

2012国际卒中大会:卒中血管内治疗转归与ASPECTS相关

 2012国际卒中大会公布的START研究初步结果显示,CTA原始图像所示的治疗前艾伯塔卒中方案早期CT评分(ASPECTS)较高与血管内治疗后转归较好相关。NCCT与ASPECTS对比研究为确定其转归预测相对准确性所必需。   目前尚无用于选择患者行血管内卒中治疗(EVT)的标准成像方法。CT依然是应用最为广泛的卒中评价方法,并且ASPECTS定量的非强化CT缺血改变(NCCT

SWIFT试验:新型血流恢复装置卒中再通率高

 在2012年国际卒中大会上,美国多中心、随机对照、采用盲法确定主要终点的SWIFT试验表明,SOLITAIRE血流恢复装置对于无症状性出血的卒中成功再通率优于MERCI装置。与MERCI治疗相比,初始SOLITAIRE治疗与更多的再灌注、更少的症状性颅内出血、死亡率降低以及卒中后3个月更多的良好神经功能结局相关。   SOLITAIRE血流恢复装置是一种自膨式支架回收器,能够在急性脑缺血时促进

空气污染与卒中住院相关

  近日,2012国际卒中大会公布的有我国研究者参与的最新研究结果表明,在污染程度大于温暖季节50%的寒冷季节,暴露于NO2和PM10在各年龄组中均与卒中住院显著相关。    卒中为美国的第3大死因,中国的第1大死因。此项研究于中国武汉实施,其空气污染程度和污染范畴高于美国和欧洲的大城市。目前有关空气污染和脑血管疾病相关性的研究较为匮乏。此项研究获取了每日二氧化氮(NO2)、二氧化硫(

CNSR研究:高血压独立预测小动脉闭塞亚型卒中复发

 在2012年国际卒中大会上,来自我国首都医科大学天坛医院的一项临床研究证实,高血压是卒中小动脉闭塞(SAO)亚型复发独立预测因素,但非大动脉粥样硬化及心因性卒中亚型复发的预测因素。该研究强调了SAO亚型卒中患者控制高血压的重要性,旨在减少在中国人群中的卒中复发事件。   高血压能否导致缺血性卒中复发仍是全球激辩的热点问题,而中国关注于此的研究较少。中国国家卒中注册研究(CNSR研究)是中国第

AXIS-2研究:G-CSF治疗急性缺血性卒中

 2012年国际卒中大会上,来自德国的一项欧洲多中心、随机、双盲、对照研究(AXIS-2研究,NCT00927836)评价了AX200对急性缺血性卒中的有效性。   AX200(粒细胞集落刺激因子,G-CSF)是一种用于治疗急性卒中的候选药物,该药物涉及了一种新型、多模式急性病理生理和促进恢复的机制。Ⅱa期临床研究显示了在较大剂量范围内,AX200对卒中患者的安全性和耐受性。AXIS-2的主

2012国际卒中大会:新型免提超声装置与tPA联合溶栓安全有效

 2012国际卒中大会公布的最新研究结果表明,应用新型免提超声溶栓装置与组织型纤溶酶原激活物(tPA)联用具有较好的安全性,并且有较高的血管再通率。此种联合疗法值得在Ⅲ期有效性试验中进一步评估。   当与静脉(IV)-tPA联用时,经FDA批准的手持式经颅多普勒(TCD)超声装置可改善再通。免提经颅超声和全身t-PA脑出血联合溶栓(CLOTBUST-HF)研究是首次在人类中实

Baidu
map
Baidu
map
Baidu
map